“Friendly staff. Dr. Schwartz explains things very well. Very clean facility.”
Ozempic, Wegovy, and Your Eye Procedure: What Patients on Semaglutide Need to Know
What Ozempic and Wegovy Are
Both medications contain semaglutide, a GLP-1 receptor agonist given as a weekly injection under the skin. Understanding how each is used and how the medication builds in your system helps explain why teams ask detailed questions before any procedure.
Ozempic is approved for managing type 2 diabetes, while Wegovy is approved for reducing excess body weight alongside dietary changes and physical activity, and for lowering the risk of serious heart events. The two brands use different dose ranges but the same active ingredient, and for the purposes of pre-procedure planning they carry the same considerations.
Semaglutide is started at a low dose and stepped up over several months to reduce stomach side effects. People who are still climbing toward their target dose, or who were recently increased, tend to have more nausea and slower stomach emptying than people who have been stable on the same dose for a long time. Your care team will ask specifically where you are in that process, because it shapes what precautions they recommend.
Earlier recommendations advised holding weekly forms of semaglutide for one week before any procedure regardless of the circumstances. More recent joint guidance from multiple specialty societies moved toward individualized assessment, meaning that people who are stable on their dose, free of stomach symptoms, and not scheduled for general anesthesia may be able to continue without stopping. Where concerns remain, some teams recommend a day of clear liquids before the procedure rather than an automatic dose hold. Neither approach is wrong; what matters is that the decision is made by the right people with the right information.
Before Retina Surgery: What Your Team Will Weigh
When surgery is planned under sedation or general anesthesia, several factors are considered together. No single factor determines the outcome automatically, and the goal is always to balance two real risks against each other.
Aspiration means stomach contents reaching the lungs under anesthesia, and it is a serious but uncommon complication that anesthesia teams already work to prevent through careful fasting instructions and airway technique. Semaglutide's effect on stomach emptying adds to that existing framework rather than replacing it. Symptoms such as nausea, vomiting, feeling full very early in a meal, and bloating are the factors that shift a patient from a lower-concern group to a higher-concern group before a procedure.
Pausing a medication that is controlling blood sugar or supporting weight management has real costs. Poorly controlled diabetes in the period around surgery can slow healing and complicate recovery. For some patients, the retinal problem being treated is urgent enough that delaying surgery to hold a dose would cause more harm than any stomach-related risk. Recent multi-society guidance is explicit that this balance should be assessed for each individual rather than applied as a blanket rule.
Going into surgery with clear answers reduces the chance of a same-day cancellation and ensures your blood sugar is managed during any dose hold.
- Will I need sedation or general anesthesia, or only a local numbing block
- Do you want me to hold my weekly injection, and for how long
- What are the exact fasting instructions and when do they start
- Who is managing my blood sugar if a dose is held
- What readings or symptoms should prompt a call before the procedure date
Write down the answers with the date attached so there is no confusion on the morning of your appointment.
Eye-Specific Side Effects of Semaglutide
Beyond the anesthesia question, semaglutide carries two eye-related risks that are important for any patient with existing retinal disease to understand. Neither should cause alarm, but both call for informed monitoring rather than guesswork.
Diabetic retinopathy is a condition where the blood vessels inside the retina are damaged by high blood sugar over time. The Ozempic prescribing label reports that in a two-year trial, diabetic retinopathy complications occurred more often in people on semaglutide than in those on placebo, and the difference was concentrated among people who already had retinopathy going into the study. The label links this temporary worsening to rapid improvement in glucose control rather than to the drug alone, and it specifically directs that people with a history of diabetic retinopathy be monitored during treatment. The practical response is a dilated eye exam before or shortly after starting, and a schedule of follow-up visits agreed with your retina care team as control improves.
The Wegovy prescribing label carries the same monitoring directive and reports diabetic retinopathy in a slightly higher proportion of treated patients compared to placebo. For patients using Wegovy for weight management who do not have diabetes, routine eye screening for this reason alone is not currently established. If you do have diabetes and are using Wegovy, the same monitoring guidance applies as with Ozempic.
NAION, or nonarteritic anterior ischemic optic neuropathy, is a sudden and usually painless loss of vision caused by reduced blood flow to the optic nerve. European regulators have concluded that NAION is a very rare side effect of semaglutide, estimated at roughly one additional case per ten thousand people treated per year. Studies have gone in both directions, with some finding a raised risk and others finding no statistically significant increase. The key practical point is knowing the warning sign: sudden vision loss in one eye during treatment warrants a same-day call to your eye doctor, not a wait-and-see approach. Stopping the medication across the board is not recommended, because the health consequences of stopping can outweigh the very small individual risk.
Most patients on semaglutide never experience an eye problem related to the medication. These symptoms, however, should send you to an eye doctor the same day, because the conditions behind them are treatable when caught early.
- A sudden drop in vision in one eye, with or without pain
- A dark curtain or shadow spreading across your field of view
- A sudden shower of new floaters or flashes of light
- A new blind spot in the center or to the side of your vision
- Severe eye pain with redness
An examination is what confirms the cause, so the call is always worth making early.
Frequently Asked Questions
These questions address the practical details that patients most often raise when managing semaglutide alongside their retinal care.
Standard fasting rules apply to procedures involving sedation or general anesthesia, not to in-office injections that use only numbing drops. Because you remain awake and keep your normal reflexes throughout an intravitreal injection, the stomach-emptying concern does not apply in the same way. That said, your clinic may still have its own pre-procedure instructions, so follow whatever guidance you receive when you book and make sure the staff knows you take this medication at that time.
It depends on what type of anesthesia your procedure requires, where you are in your dosing schedule, and whether you have any stomach-related symptoms. Some centers continue to follow a standard one-week hold for weekly semaglutide before any procedure under sedation. Others apply individualized criteria and may allow you to continue if you are stable and symptom-free. Both approaches reflect the current state of evidence, so ask your team which approach they use and make sure your prescribing provider is included in the plan so blood sugar coverage is arranged if a dose is held.
Tell your care team when you arrive rather than staying quiet about it. Anesthesia teams have options available when a patient has a recent dose on board, including treating the stomach as potentially full, using an ultrasound scan to check stomach contents, or adjusting the anesthetic approach. None of those options are available if the team does not know. Disclosing what you took and when you took it gives them the information they need to proceed as safely as possible.
Having existing retinopathy means your eyes should be monitored more closely as glucose control improves, not that you should avoid a medication that may protect your heart, kidneys, and nerves. The temporary worsening described in the prescribing label is linked to rapid drops in blood sugar rather than to the drug alone, and it is most relevant during the early phase of treatment. A dilated eye exam before or shortly after starting, and a clear follow-up schedule, gives your care team a baseline to measure any changes against. Bring this topic up with both your prescribing provider and your retina care team.
Yes. Multi-society guidance addresses the GLP-1 receptor agonist class as a whole, not just semaglutide specifically. Medications such as dulaglutide and liraglutide, and the related medication tirzepatide, belong on your pre-procedure medication list for the same reasons. What varies across these drugs is the dosing interval and how far along a patient is in building up the dose, which is why teams ask for the exact drug name, the specific dose, and the date of the last injection rather than simply a class name.
As soon as the procedure is scheduled, and ideally at least two weeks before the date. That window gives the procedure team and your prescribing provider enough time to agree on a plan, arrange any blood sugar coverage that may be needed, and avoid a same-day cancellation. If your procedure is being scheduled urgently because of an acute retinal problem, share your medication name, dose, and last injection date at your very first contact with the office.
Visit Atlantic Retina Center for Expert Retinal Care
At Atlantic Retina Center, our fellowship-trained, board-certified retina specialists are experienced in caring for patients with complex medical histories, including those managing diabetes with newer medications. We offer comprehensive retinal evaluation and treatment across our offices serving the Eastern Shore of Maryland and central and southern Delaware. If you have questions about your upcoming procedure or want to schedule a dilated eye exam, we are ready to help you move forward with confidence.